Please find all related articles below.
EPHA, together with US consumer organisation SumOfUs and UK-based Ethical Consumer, has co-signed letters to some of the world’s leading pharmaceutical companies, asking for information on their sources of active pharmaceutical ingredients (APIs) and their production practices.
The recent report, ’Bad Medicine’ published by SumOfUs, provides the context for the letters. It exposes the fact that a number of large pharmaceutical companies are sourcing antibiotic ingredients (...)
Over 22,000 people were infected with measles across the EU in 2014 and 2015, including one measles-related death. The only effective preventive measure against measles remains vaccination. The recent outbreaks suggest a growing number of susceptible people are not being vaccinated. The reasons for this are varied, including a growing number of parents who are reluctant to vaccinate their children and increasing barriers of access to vaccination. To avoid further such outbreaks, it is thus (...)
The June Uppsala Health Summit (UHS), ‘A World Without Antibiotics’ expanded the discussion about antimicrobial resistance (AMR) at European and national level by examining this critical health threat from different angles. Among the key themes discussed were access to antibiotics and to improved diagnostics, the environmental dimension of AMR, collaborative research & innovation, and economic models allowing pharma companies to balance profits and investments for the public (...)
Access to Medicines
Pharmaceuticals and Medicines
Vaccines and Immunization
complementary and alternative medicine
Antimicrobial Resistance (AMR)
A new report released on 11 June 2015 by global consumer watchdog SumOfUs.org provides a new angle to the debate about the major health threat of antimicrobial resistance (AMR): the improper disposal of pharmaceutical waste by polluting factories in China, and their links with some of the world’s biggest pharmaceutical companies. The report raises the urgent need for antibiotic stewardship to avoid a looming public health disaster.
According to the report, polluting factories in (...)
On 25 May 2015, the 68th World Health Assembly (WHA) - the supreme decision-making body of WHO which convenes annually in Geneva - agreed resolutions to tackle antimicrobial resistance and improve access to affordable vaccines.
Tackling antimicrobial drug resistance
The global importance and seriousness of AMR was highlighted by German Chancellor Angela Merkel, who told delegates on the opening day that addressing AMR is one of the highest health priorities for the world.
Following a (...)
On 29 April 2015, Public Health England organised a workshop for the European Commission in Luxembourg on the joint procurement of medical countermeasures, which featured a host of speakers from different Commission Directorate Generals, EMA, ECDC, WHO, and industry. One of the key messages was that the new Joint Procurement Agreement (JPA) tool is potentially available for many different countermeasures as long as they fall into the legal framework of serious cross-border health threats. (...)
In recent years, antimicrobial resistance (AMR) has been identified as a major health threat. The 2014 European Antibiotic Awareness Day drew attention to the consequences arising from the overuse and misuse of antibiotics, for instance through self-medication.
The emergence of multi-drug resistant ’superbugs’ as a result is a serious threat to health throughout Europe.
European Health Ministers recently issued Council conclusions which expand the EU level discourse about (...)
On 1 December 2014, the Council of Health Ministers released its conclusions regarding vaccinations as an effective tool in public health. They invite national governments and the European Commission (EC) to increase information exchanges with the European Centre for Disease Prevention and Control (ECDC) and the World Health Organization (WHO) to focus on risk groups, and convey informed and clear messages on vaccination.
The EPSCO conclusions adopted under the Italian Presidency - which (...)
“Placing pharma policy in DG Enterprise was justified. It has traditionally been in DG Enterprise, but was moved to DG Sanco and has once again been instated as an Enterprise competence” said during her hearing Commissioner-designate Elzbieta Bienkowska.
By Dorota Sienkiewicz,Health Equity and Policy Coherence Coordinator, and Martyna Giedrojć, EPHA Policy Officer for Health Systems
The pharmaceutical industry is the biggest sector in the world. In terms of production, (...)
Brussels, 2 October 2014 - We are writing to support Member States who have already expressed their concerns on the decision of European Commission President Elect Jean-Claude Juncker to move the competence for medicinal products and health technologies from the Commissioner in charge of Health to the Commissioner in charge of Internal Market and Industry within the new Commission. We would like to ask for your full support to have that decision reversed.
Dear Head of States, Dear Prime (...)